Stock Updates

A look at a High Market Cap Stock: Vertex Pharmaceuticals Incorporated, VRTX

Vertex Pharmaceuticals Incorporated, VRTX is in the exchange NASDAQ and its industry is Biotechnology in the sector of Healthcare. Based in USA, Vertex Pharmaceuticals Incorporated, VRTX  has a market cap of 20870.43. Since its IPO date on the 7/24/1991, Vertex Pharmaceuticals Incorporated, VRTX performance year to date is -31.32%. Today Vertex Pharmaceuticals Incorporated, VRTX has gained -0.43%, with a current price of 86.42.

Ownership of the company is 0.30% for insider ownership while institutional ownership is 97.80%. The management of the company have seen the company have a payout ratio of *TBA. Return of assets are at -11.00%, with return on investment at -28.20%.

In terms of debt levels and profit levels, Vertex Pharmaceuticals Incorporated, VRTX is seeing a long-term debt/equity of 0.59. While Total debt/equity is 0.84. With a profit margin of -17.70%, this is combined with a gross margin of 88.00%, and operating margin of -8.70%. Vertex Pharmaceuticals Incorporated ability to meet debt levels, with a current ratio of 2.3, while the quick ratio is 2.2.

For the last year Vertex Pharmaceuticals Incorporated, VRTX has seen a EPS growth of 26.50%. A performance for the year of -24.54%. The 52-week high is -35.85%, and the 52-week low is 13.86%. The average volume for Vertex Pharmaceuticals Incorporated, VRTX is 1078663.

With a target price of 108.84, can Vertex Pharmaceuticals Incorporated, VRTX reach this target? Looking at the value indicators of Vertex Pharmaceuticals Incorporated, VRTX. Vertex Pharmaceuticals Incorporated has a P/E of *TBA and a forward P/E of 31.27. Perhaps the more useful indicator than P/E, is PEG which has a value of *TBA. Vertex Pharmaceuticals Incorporated also has a P/S and a P/B of 13.4 and 21.55 respectively. For P/cash, Vertex Pharmaceuticals Incorporated has a value of 19.48, while it is 77.3 for P/free cash flow.

At the current price of 86.42, Vertex Pharmaceuticals Incorporated has a dividend yield of *TBA. We see a return on equity of -28.90%.

Looking more long-term Vertex Pharmaceuticals Incorporated, is projected to get an EPS growth for the next five years of 54.03%. In the short-term an EPS growth of 206.09% in the next year is forecasted. This is after a EPS growth of 26.50% for this year and for the last five years a 9.30% growth has been seen.

Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.

About the author

Peter Clarke

Leave a Comment